David Sinclair· PhD
UBX1967, a senolytic small inhibitor of the Bcl-2 family, has been in-licensed by Unity Biotech to treat age-related diseases of the eye, and will enter preclinical studies.
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
UBX1967, a senolytic small inhibitor of the Bcl-2 family, has been in-licensed by Unity Biotech to treat age-related diseases of the eye, and will enter preclinical studies.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
interestingly we've shown in animals that they don't cause that to happen in normal healthy eyes they only target cells that have been damaged by the disease process and the stress associated with disease process
diseases of the eye is you have a series of these untreatable diseases that make you blind where we think senescence could play a role and we're going to explore each of these in the clinic
both of them are inhibitors of the bcl-2 protein family so these are molecules that inhibit inhibitors of apoptosis so they cause cells to enter program to solve death
the apoptosis program only turns on in the disease State and it was a pretty awesome result because you can see the selectivity of molecules in a living creatures eye
so now they're looking at the eye because again it's it's a nice indication where for some of these eye diseases there isn't any solution and you you can in principle target it quite precisely to the eye so yeah i think that is exactly the strategy that people will be taking